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Review
Efficacy of Stem Cell Therapy
for Tendon Disorders
A Systematic Review
Noortje Anna Clasina van den Boom,*† MD, Marinus Winters,‡ PhD,
Hidde Jacobs Haisma,§ PhD, and Maarten Hendrik Moen,k{# MD, PhD
Investigation performed at Maastricht University, Maastricht, the Netherlands
Background: Stem cell therapy is an emerging treatment for tendon disorders.
Purpose: To systematically review the efficacy of stem cell therapy for patients with tendon disorders.
Study Design: Systematic review; Level of evidence, 4.
Methods: MEDLINE/PubMed, EMBASE, CINAHL, CENTRAL, PEDro, and SPORTDiscus; trial registers; and gray literature were
searched to identify randomized controlled trials (RCTs) and non-RCTs, cohort studies, and case series with 5 or more cases.
Studies investigating any type of stem cell therapy for patients with tendon disorders were eligible if they included patient-reported
outcome measures or assessed tendon healing. Risk of bias was assessed through use of the Cochrane risk of bias tools.
Results: This review included 8 trials (289 patients). All trials had moderate to high risk of bias (level 3 or 4 evidence). In Achilles
tendon disorders, 1 trial found that allogenic-derived stem cells led to a faster recovery compared with platelet-rich plasma.
Another study found no retears after bone marrow–derived stem cell therapy was used in addition to surgical treatment. There were
4 trials that studied the efficacy of bone marrow–derived stem cell therapy for rotator cuff tears. The controlled trials reported
superior patient-reported outcomes and better tendon healing. A further 2 case series found that stem cell therapy improved
patient-reported outcomes in patients with patellar tendinopathy and elbow tendinopathy.
Conclusion: Level 3 evidence is available to support the efficacy of stem cell therapy for tendon disorders. The findings of available
studies are at considerable risk of bias, and evidence-based recommendations for the use of stem cell therapy for tendon dis-
orders in clinical practice cannot be made at this time. Stem cell injections should not be used in clinical practice given the lack of
knowledge about potentially serious adverse effects.
Keywords: tendinopathy; tear; injection; Achilles; shoulder
Tendon disorders are common in athletes and include ten-
dinopathy and partial or complete tendon tears.4 Tendino-
pathy is characterized by pain, swelling, and impaired
performance.1,26 In some sport disciplines, such as volley-
ball, more than 50% of athletes develop tendinopathy
during their athletic career.23 The Achilles tendon is the
most commonly affected tendon in runners, and approxi-
mately 30% of runners will develop Achilles tendinopathy
at some point.1,26 Tendon tears represent more severe
injuries than tendinopathy, and outcomes of tendon tears
are often poorer, particularly for rotator cuff tears of the
shoulder.20
Various treatment modalities for tendon disorders have
been described, such as exercise therapy,12,29 shockwave
therapy, nonsteroidal anti-inflammatory drugs, and
injection therapy with, for example, corticosteroids, scleros-
ing substances (aethoxysclerol),31 and autologous blood
products.1 Surgery may be required in patients with per-
sistent tendon symptoms or young patients with severe
tendon tears.9 Despite the abundance of available treat-
ment modalities, outcomes of tendon disorder treatments
are often not satisfactory.5
Over the past decade, several studies have shown prom-
ising results of stem cell therapy in individuals with tendon
disorders.3,37 Nevertheless, a systematic review performed
by our research group in 2017 concluded that there was no
evidence for use of stem cell therapy in tendon disorders.33
Given the increasing use of stem cell therapy in clinical
practice, the absence of evidence for or against the use of
stem cell therapy in 2017, and new studies having become
available on the topic in the past 2 years, an update of our
study was warranted.17,18,41,48 Therefore, the main purpose
of the current systematic review was to reevaluate the effi-
cacy of stem cell therapy based on patient-reported outcome
The Orthopaedic Journal of Sports Medicine, 8(4), 2325967120915857
DOI: 10.1177/2325967120915857
ª The Author(s) 2020
1
This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (https://creativecommons.org/
licenses/by-nc-nd/4.0/), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are
credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For article reuse guidelines, please visit SAGE’s website at
http://www.sagepub.com/journals-permissions.
measures (PROMs) and tendon healing in individuals with
tendon disorders.
METHODS
Protocol Registration and Reporting
This study was registered on PROSPERO (CRD42019116828)
on January 10, 2019, before any synthesis was commenced.
The PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) guidelines were followed for
planning, conducting, and reporting this study.28
Research Question and Inclusion
and Exclusion Criteria
The research question was to assess the efficacy of stem cell
therapy (any type) on PROMs and tendon healing in
patients with tendon disorders (any type). Our primary out-
comes were PROMs, and our secondary outcome measures
were tendon healing measured with magnetic resonance
imaging (MRI) or ultrasonography. The inclusion and
exclusion criteria are summarized in Table 1.
Search Strategy
A sensitive search strategy was used as previously
described.33 This strategy was based on indexed and free
text terms and composed in collaboration with a research
librarian (see Appendix 1, available as supplemental mate-
rial). The electronic databases MEDLINE/PubMed, CEN-
TRAL, EMBASE, CINAHL, PEDro, and SPORTDiscus
were searched from inception to November 2018 by 2 inde-
pendent authors (N.A.C.v.d.B. and M.H.M.). We did not
apply any restrictions to our search strategy. Reference lists
of included studies were scanned to identify any additional
relevant reports. Inaddition,wesearched for ongoing trials in
several national (http://www.trialregister.nl) and interna-
tional (http://www.controlled-trials.com) trial registries, the
WHO trial register (apps.who.int/trialsearch), the EU clini-
cal trial register (http://www.clinicaltrialsregister.eu), and
ClinicalTrials.gov. We attempted to contact primary investi-
gators to collect additional information about trials identified
through these sources. Last, we searched for unpublished
studies in OpenGrey (http://www.opengrey.eu), the British
Library Inside (http://explore.bl.uk/primo_library/libweb/
action/search.do?vid¼BLVU1), Web of Science, and BIOSIS
previews (http://www.ovid.com.). Authors of potentially eligi-
ble studies were contacted for additional information on their
studies.
Study Selection
After removal of duplicates, 2 authors (N.A.C.v.d.B. and
M.H.M.) independently screened titles and abstracts for
potential eligible studies. Subsequently, both authors inde-
pendently appraised full-text content and applied our inclu-
sion and exclusion criteria. Discrepancies in inclusion of
articles were resolved by a third reviewer (M.W.).
Data Extraction
A standardized data extraction sheet was adopted from the
Cochrane Collaboration Centre and modified for the pur-
pose of our study.43 Data extraction was performed by 2
authors (N.A.C.v.d.B. and M.H.M.) independently, includ-
ing study design, year of publication, duration of follow-up,
study population characteristics (eg, mean age, sex
TABLE 1
Inclusion and Exclusion Criteriaa
Inclusion criteria
 Published or unpublished studies; randomized or
nonrandomized trials and case series with 5 cases
 Individuals diagnosed with a tendon disorder based on physical
examination or imaging (eg, MRI, ultrasonography)
 Study reported at least 1 of the following:
♦ Patient-reported outcomes such as functional scales (eg,
VISA-A), pain scales, time to recovery (or return to play),
and/or recurrences
♦ Tendon healing as measured with MRI or ultrasonography
 Stem cells of any origin (bone marrow, adipose tissue, etc) used
as a treatment
 For controlled trials, the comparison of efficacy of stem cell
therapy with another treatment modality or no intervention
Exclusion criteria
 Trials that included patients with tendinopathy who had other
concurrent injury
aThese criteria were similar to the criteria previously used by
Pas et al.33 We reported recurrent tendon disorders, as measured
with patient-reported outcomes, as an additional outcome mea-
surement. MRI, magnetic resonance imaging; VISA-A, Victorian
Institute of Sport Assessment–Achilles questionnaire.
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distribution), tendon injury type and location, stem cell
type, injection frequency, primary and secondary outcome
measurements, and main results of the studies. Disagree-
ments were resolved by a third reviewer (M.W.).
Risk of Bias Assessments
Risk of bias was assessed independently by 2 authors
(N.A.C.v.d.B., M.H.M.) for each outcome in each study.
The Cochrane Risk of Bias (RoB 2) tool was used to assess
the 5 major domains of biases.42 This tool provides an
algorithm to reach an overall risk of bias judgment per
study outcome. The 2 authors independently assessed bias
(1) arising from the randomization procedure, (2) due to
deviations from the intended interventions, (3) due to
missing outcome data, (4) in measurement of the outcome,
and (5) in selection of the reported result to make an over-
all risk of bias judgment for each study outcome. Each
domain was completed after the signaling questions as
proposed by the guidance of the RoB 2 tool.
Each separate domain was labeled as “low risk of bias,”
“some concerns,” or “high risk of bias.” Outcomes of ran-
domized controlled trials (RCTs) were considered to have
low risk of bias for the overall judgment when all 5 domains
of bias were scored “low risk of bias.” RCT outcomes were
considered to entail some concerns for the overall risk of
bias if at least 1 of the 5 domains was judged as having
“some concerns” about bias. RCT outcomes were considered
to have high risk of bias for the overall judgment if at least 1
of the 5 domains of bias was scored as “high risk of bias.” In
case of disagreement between the 2 authors, a third
reviewer (M.W.) made the final decision.
The Risk Of Bias In Non-randomised Studies–of Inter-
ventions (ROBINS-I) was used to assess risk of bias in
non-RCTs, and the Newcastle Ottawa Scale was used to
assess the quality of case series. Using the Newcastle
Ottawa Scale, a maximum of 6 stars could be awarded. Six
stars indicated perfect quality, whereas 0 stars indicated
very low quality. Appendices 2 through 5 provide details.
Data Synthesis
Data synthesis was planned for RCTs if at least 2 studies
investigated the same treatment comparison and studies
were clinically homogeneous (ie, identical stem cell type
and tendon disorder, cointerventions, mode of injection or
transplant). The mean difference expressed the compara-
tive efficacy if studies used the same outcome measure.
Standardized mean differences expressed comparative effi-
cacy for studies that used different measures to estimate
treatment effects. P values less than .05 were considered
significant for all analyses. Fixed-effects models were
planned to pool data that were statistically homogeneous
or when fewer than 3 studies were available for data syn-
thesis. We used random effects models if statistical hetero-
geneity was present and when 3 or more studies were
available. If heterogeneity was present and a sufficient
number of studies were available (n  10), we planned a
subgroup analysis or meta-regression analysis to explore
potential sources for heterogeneity (age and sex).
Descriptive synthesis was performed when data pooling
was not possible.
Levels of Evidence
Levels of evidence were assigned to further specify the
strength of the studies as proposed by the Oxford Centre for
Evidence-Based Medicine (Table 2).44 Following this system,
RCTs at low risk of bias were graded as level 2 evidence, non-
RCTs at low risk of bias were considered level 3 evidence, and
case series were considered level 4 evidence. The level of evi-
dence of individual studies could be downgraded based on
study imprecision, risk of bias, and study indirectness or
because of small effect sizes. The level of evidence of individ-
ual studies could be upgraded based on large effect size.
RESULTS
Study Selection
We included 8 trials, including 4 recent trials that were not
included in our 2017 systematic review.16,23,41,48 Figure 1
shows the study flow diagram. We identified 4 unpublished
trials in trial registries.15,39,40,47 We made attempts to con-
tact the authors of these trials by email. The authors of 1
trial replied and reported that their trial was under
review.9 The authors of the other 3 trials did not provide
information about the status of their trials.
Study Characteristics
Of the 8 studies included in this review, 1 was an RCT,48 3
were non-RCTs,14,17,18 and 4 were case series.12,22,34,41 These
studies focused on stem cell therapy for tendon disorders of
the lateral elbow22 and rotator cuff12,14,17,18 and the Achil-
les41,48 and patellar tendon,34 including a total of 289
patients (135 males, 154 females; age range, 14-74 years).
The study populations consisted of athletes and nonathletes.
Study characteristics are summarized in Table 3.
Of the 8 studies, 3 studies evaluated the efficacy of allo-
genic adipose-derived stem cells (allo-ASCs).18,22,48 The
efficacy of bone marrow mononuclear stem cells (BMMCs)
was investigated in 2 studies,12,34 the efficacy of bone mar-
row aspirate concentration (BMACs) in 2 studies,17,41 of
TABLE 2
Oxford Centre for Evidence-Based Medicine 2011
Levels of Evidence for Interventionsa
Level 1 Systematic reviews
Level 2 Randomized controlled trials with low/moderate risk of
bias or observational studies with dramatic effect
Level 3 Non–randomized controlled trials with low/moderate risk
of bias or randomized controlled trials at high risk of bias
Level 4 Case series, case-control studies, historically controlled
studies, or non–randomized controlled trials at high
risk of bias
Level 5 Mechanism-based reasoning/expert opinion
aFrom Oxford Centre for Evidence-Based Medicine.44
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which 1study combined BMACs with platelet-rich plasma
(PRP).17 Efficacy of stem cell therapy was measured using
PROMs in 7 of the 8 studies.12,17,18,22,34,41,48 In 1 study,14
the investigators assessed efficacy of treatment using MRI
and ultrasonography. In 7 of the 8 studies,12,14,17,18,22,34,48
investigators evaluated tendon healing using MRI or ultra-
sonography. Due to study heterogeneity, descriptive data
synthesis was performed.
Risk of Bias in Individual Trial Outcomes
Domain-based risk of bias assessments for the non-RCTs
and RCTs are presented in Table 4. The RCTs examined the
efficacy of stromal vascular fraction (allo-ASC) versus PRP
injection in patients with tendinopathy based on PROMs,
MRI, and ultrasonography.48 High risk of bias was found
for the overall judgment. The non-RCTs were found at high
or moderate risk of bias for all PROMs. Ultrasound out-
comes were found at moderate risk of bias for the overall
judgment. Only MRI outcomes were found at low risk of
bias in 1 non-RCT that investigated the efficacy of allo-
ASC injection versus arthroscopic rotator cuff repair.18
Quality of case series varied; they received between 2 and
5 stars out of 6 stars in total. See Appendices 2 and 3 for all
risk of bias judgements.
Efficacy of Stem Cell Injections for Tendon Disorders
Achilles Tendon Disorders
Achilles Tendinopathy. Usuelli et al48 examined the effi-
cacy of allo-ASC injection versus PRP injection in patients
with noninsertional Achilles tendinopathy with a total
follow-up of 6 months. At 15 days after treatment, the mean
American Orthopaedic Foot and Ankle Society (AOFAS)
score was significantly higher in the allo-ASC group than
in the PRP group (80 vs 67, respectively; P< .05). The mean
visual analog scale (VAS) score was significantly lower in
the allo-ASC group than the PRP group at 15 days after
treatment (2.5 vs 4.5, respectively; P < .05). There was no
difference between the groups in the Victorian Institute of
Sports Assessment–Achilles questionnaire (VISA-A) score
at 15 days of follow-up (P > .05). At a follow-up of 30 days,
the mean VAS pain score was 2.0 in the allo-ASC group
and 4.0 in the PRP group (P< .05). The mean VISA-A score
was 60 in the allo-ASC group and 47 in the PRP group (P<
.05). The AOFAS score was 80 in the allo-ASC group and 70
in the PRP group (P> .05). After 60 days of follow-up, there
were no differences in PROMs between patients treated
with allo-ASC and PRP injection.
Achilles Tendon Tears. Stein et al41 examined the out-
comes of primary Achilles tendon rupture repair with BMAC
Studies included in qualitative
analysis
(n = 8)
Records screened by title and
abstract 
(n = 812)





Full-text articles excluded with reason
(n = 5)





No stem cells injected
(n = 1)
No data of interest due to 











database searching and trial
registers
(n = 1301)
Figure 1. Study flowchart based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.





Design Sample Size Injury Type Demographicsb Treatment Outcome Measures Follow-up
Level of
Evidence
Usuelli48 (2018) RCT Group 1: n ¼ 23
























N ¼ 27 Achilles tendon
rupture
 Age, 38.3 ± 9.6
 Females, 6
(22%)
BMAC  Mean difference in calf
circumference (cm)
 Time to walking without
boot (mo)





Group 1: n ¼ 35
Group 2: n ¼ 35
Rotator cuff tear Group 1 (C)




















Group 1: n ¼ 45
Group 2: n ¼ 45
Rotator cuff tear Group 1 (C)








 MRI for number of stem
cells correlated for cuff
healing







Group 1: n ¼ 12








 Age, 54.9 ± 7.6
 Females, 7
(58%)
















N ¼ 14 Rotator cuff tear  Age, 59.2
 Females, 9
(64%)
BMMC  UCLA score






N ¼ 8 Patellar
tendinopathy
 Age, 24 (14-35)
 Females, 4
(50%)










N ¼ 12 Lateral
epicondylar
tendinopathy
 Age, 51.8 ± 9.5
 Females, 6
(58%)





aAOFAS, American Orthopaedic Foot and Ankle Society; ASC, adipose-derived stem cell; ASES, American Shoulder and Elbow Surgeons;
ATRS, Achilles Tendon Rupture Score; BMAC, bone marrow aspirate concentrate; BMMC, bone marrow mononuclear cells; C, comparison
group; I, intervention group; IKDC, International Knee Documentation Committee; KOOS, Knee injury and Osteoarthritis Outcome Score;
MEPI, Mayo Elbow Performance Index; MMT, manual muscle test; MRI, magnetic resonance imaging; MSC, bone marrow-derived mesen-
chymal stem cells; PRP, platelet-rich plasma; RCT, randomized controlled trial; ROM, range of movement; SF-12, 12-Item Short Form Health
Survey (mental and physical); SF-36, 36-Item Short Form Health Survey questionnaire; UCLA, University of California, Los Angeles; VAS,
visual analog scale; VISA-A, Victorian Institute of Sport Assessment–Achilles questionnaire.
bAge is expressed in years as mean or mean ± SD, with range (if available) in parentheses. Data for female participants are expressed as n (%).
cAge and sex were not clearly described; the authors only mentioned there was no significance difference with comparison group.
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augmentation. In that study, 27 patients underwent open
repair procedures augmented with BMAC injection. All
patients could walk without a boot at 1.8 ± 0.7 months and
participated in light activity at 3.4 ± 1.8 months, and 25 of 27
patients (92%) returned to sport at 5.9 ± 1.8 months. At a
mean follow-up of 29.7 ± 6.1 months, no reruptures of Achilles
tendons were reported. The mean Achilles Tendon Rupture
Score at final follow-up was 91 points (range, 72-100 points).
Level of Evidence. There is level 3 evidence for a
superior effect of allo-ASC injections for Achilles tendi-
nopathy compared with PRP injections on PROMs at 15
and 30 days after injection, but no differences were
observed at 60 days of follow-up. There is level 4 evi-
dence for improved PROMs and absence of reruptures
2.5 years after open Achilles tendon repair with BMAC
augmentation.
TABLE 4
Risk of Bias Judgment for Randomized and Nonrandomized Controlled Trialsa
Randomized Controlled Trial
Usuelli et al48 (2018)
Outcome Primary: VAS, VISA-A, AOFAS, SF-36
Secondary: MRI, US
Intervention vs control groups Intervention: allo-ASC injection
Control: PRP injection
Risk of bias
Bias arising from the randomization process Some concerns
Bias due to deviations from intended interventions High risk
Bias due to missing outcome data Low risk
Bias in measurement of the outcome Intervention: some concerns
Control: low risk
Bias in selection of the reported result Some concerns
Overall risk of bias judgment High risk
Nonrandomized Controlled Trials
Kim et al17 (2018) Kim et al18 (2017) Hernigou et al14 (2014)



























Bias in selection of participants into the study Low risk Moderate risk Moderate risk
Bias in classification of interventions Low risk Low risk Moderate risk
Bias due to deviations from intended interventions Low risk Low risk Low risk
Bias due to missing data Low risk Low risk Low risk







Bias in selection of the reported result Moderate risk Low risk Low risk







aRisk of bias judgments apply to all study outcomes listed unless otherwise specified. AOFAS, American Orthopaedic Foot and Ankle
Society; ASC, adipose-derived stem cell; ASES, American Shoulder and Elbow Surgeons; BMAC, bone marrow mononuclear stem cell; MMT,
manual muscle test; MRI, magnetic resonance imaging; MSC, bone marrow-derived mesenchymal stem cells; PROM, patient-reported
outcome measure; PRP, platelet-rich plasma; ROM, range of movement; SF-36, 36-Item Short Form Health Survey questionnaire; UCLA,
University of California, Los Angeles; US, ultrasonography; VAS, visual analog scale; VISA-A, Victorian Institute of Sports Assessment–
Achilles questionnaire.
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Rotator Cuff Tendon Tears
We identified 3 non-RCTs that examined the efficacy of
stem cell injections in rotator cuff tendon tears. The first
trial determined the efficacy of allo-ASC injection during
arthroscopic rotator cuff repair, comparing the double-row
suture bridge technique with injection versus the double-
row suture bridge technique alone in patients with rotator
cuff tears.18 At 21 months of follow-up, the mean Constant
score was 78.3 ± 14.9 in the intervention group and
80.1 ± 13.2 in the control group (P ¼ .634). The mean Uni-
versity of California, Los Angeles (UCLA) Shoulder Rating
Scale score was 29.8 ± 5.1 in the intervention group and
30.5 ± 4.8 in the control group (P ¼ .302). The mean VAS
pain score at rest was 0.4 ± 0.6 for the allo-ASC group and
0.3 ± 0.5 for the control group (P ¼ .776). The VAS pain
score during motion was 2.4 ± 1.1 in the allo-ASC group
and 2.1 ± 0.9 in the control group (P ¼ .256). At minimum
of 12 months after intervention, a retear rate of 28.5% was
found with MRI in the control group versus 14.3% in the
stem cell injection group (P< .001). Complete healing of the
tendon, as measured with MRI, was observed in 85.7% of
patients in the intervention group versus 71.4% of patients
in the control group.
The second trial evaluated the efficacy of bone marrow–
derived mesenchymal stem cells (MSCs) injection as an
adjunct to single-row rotator cuff arthroscopy in compari-
son with single-row rotator cuff arthroscopy alone in
patients diagnosed with rotator cuff tears.14 The total
follow-up was 10 years. In the BMAC group, significantly
fewer retears were reported after 10 years of follow-up as
measured by MRI and ultrasonography (13% vs 56%,
respectively; P < .05).
The third trial studied the efficacy of an injection with
BMAC-PRP versus exercise therapy in patients diag-
nosed with a rotator cuff tear with a total follow-up of
3 months.17 At 3 weeks postoperatively, mean VAS pain
scores were 2.3 ± 0.8 in the BMAC-PRP group and 3.6
± 2.3 in the control group (P ¼ .147). The mean American
Shoulder and Elbow Surgeons (ASES) score was 74.1 ±
8.4 in the BMAC-PRP group versus 62.2 ± 12.2 in the
control group at final follow-up (P ¼ .011). The mean
VAS pain score was 1.9 ± 0.7 in the intervention group
and 3.7 ± 1.8 in the control group at final follow-up
(P ¼ .039).
In addition, 1 case series examined the efficacy of BMMC
augmentation in patients undergoing surgery for complete
rotator cuff tears. In that series, 14 consecutive patients
were treated with transosseous stitches through mini-
open incision and subsequent BMMC injection obtained
from the iliac crest.12 The minimum follow-up was 12
months. The UCLA score was used as main outcome; this
score increased from 12 ± 3.0 to 31 ± 3.2, and no statistical
analysis was performed in this study.
Level of Evidence. There is level 3 evidence for a supe-
rior effect of allo-ASC injection augmentation for rota-
tor cuff tears compared with arthroscopic double-row
suture bridge technique alone on tendon healing and
retears as measured by MRI. However, no significant
differences have been observed between surgical
rotator cuff repair with and without allo-ASC augmen-
tation on PROMs (level 3). There is level 3 evidence for
a superior effect of arthroscopic single-row rotator cuff
repair with BMMC augmentation in comparison with
arthroscopic single-row rotator cuff repair for retears
as measured by MRI and ultrasonography. There is
level 4 evidence for a superior effect of BMAC-PRP on
rotator cuff tears compared with exercise therapy for
the ASES score and VAS pain score at 3 months after
injection. Table 2 provides more information about the
level of evidence.
Patellar Tendinopathy
One case series studied the efficacy of BMMC injection
for patients with chronic patellar tendinopathy (lasting
at least 6 months).34 The follow-up time of the patients
was at least 24 months. The following PROMs increased
significantly over time: Tegner Activity Scale score (P ¼
.006), International Knee Documentation Committee
score (P ¼ .047), and Knee injury and Osteoarthritis
Outcome Score (KOOS) for the subdomains Activities of
Daily Living (P ¼ .008) and Function during Sports/Rec-
reation (P ¼ .0078). No statistical improvement was
observed for the Lysholm score (P ¼ .1043), KOOS for
Pain (P ¼ .2399), KOOS for Quality of Life (P ¼ .0825),
and 12-item Short Form Health Survey questionnaire for
mental and physical domains (P ¼ .5589 and P ¼ .438,
respectively). Tendon structures, as assessed with ultra-
sonography, did not change between baseline and follow-
up.
Level of Evidence. There is level 4 evidence for improved
PROMs after BMMC injections for patients with chronic
patellar tendinopathy at least for 24 months of follow-up.
Lateral Elbow Tendinopathy
Lee et al22 studied the efficacy of an allo-ASC injection in a
case series of patients with lateral elbow tendinopathy. The
total follow-up period was 52 weeks. The Mayo Elbow Per-
formance Index was 64.0 ± 13.5 at baseline and 87.1 ± 11.6,
89.2 ± 6.8, 92.1 ± 6.1, and 90.6 ± 5.8 after 6, 12, 23, and 52
weeks, respectively. Compared with baseline, these were
significant improvements at all follow-up points (P ¼ .002).
The VAS pain score during motion was 66.8 ± 14.6 at base-
line, 42.1 ± 23.2 at 6 weeks after injection (P ¼ .004), 31.1 ±
20.6 at 12 weeks (P ¼ .002), 15.3 ± 13.7 at 26 weeks (P ¼
.002), and 14.8 ± 13.1 at final follow-up at 52 weeks (P ¼
.002). The VAS scores after 26 and 52 weeks were also sig-
nificantly lower than those at 6 weeks (P ¼ .006 and P ¼
.008, respectively) and at 12 weeks after injection (P ¼ .013
and P¼ .034, respectively). For ultrasound evaluation of the
tendon structure, the largest average defect area was 6.46 ±
3.37 mm2 at baseline, 2.34 ± 1.42 mm2 after 26 weeks, and
3.06 ± 1.32 mm2 (P ¼ .003) after 52 weeks for the longitudi-
nal axis. For the transverse axis, the average largest defect
area was 8.14 ± 3.99 mm2 at baseline, 3.36 ± 1.94 mm2 after
26 weeks (P¼ .002), and 4.31 ± 2.10 mm2 after 52 weeks (P¼
.015).
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Level of Evidence. There is level 4 evidence for improved
PROMs and ultrasound evaluation of the tendon healing
after allo-ASC injection at all follow-up periods.
DISCUSSION
The purpose of this systematic review was to evaluate the
evidence of stem cell therapy in the treatment of tendon
disorders. To date, the efficacy of stem cell therapy has been
examined in 8 studies of Achilles tendon, rotator cuff ten-
don, and patellar tendon disorders and lateral elbow tendi-
nopathy.12,14,17,18,22,34,41,48 We found level 3 evidence for
the superior effect of stem cell therapy compared with
treatment without stem cells. This update shows that there
is still a moderate to high risk of bias for studies evaluating
stem cell therapy for tendon disorders.
How Does the Evidence for Stem Cell Therapy
Compare With the Evidence for Other Treatments
for Tendon Disorders?
Level 3 evidence for the use of stem cell therapy in tendon
disorders implies that we cannot yet recommend its use in
clinical practice. Except in the trial by Kim et al,18 stem cell
therapy has not been compared with commonly used ther-
apies such as exercise therapy or extracorporeal shockwave
therapy (ESWT). Moreover, the duration of follow-up was
relatively short in the trial by Kim et al.17 This makes it
challenging to judge whether stem cell therapy should be
preferred over conventional treatments in the management
of tendon disorders.
Compared with stem cell therapy, other therapies have a
larger body of evidence underpinning their efficacy,
although their evidence is also moderate to low. A recent
systematic review on the treatment of Achilles tendinopa-
thy concluded that eccentric exercises may be better than
wait-and-see and traditional physiotherapy.29 The evi-
dence for this was, respectively, very low and low. Another
commonly applied intervention for Achilles tendinopathy is
ESWT. The recent systematic review by Korakakis et al19
reported that low-level evidence is available to show ESWT
comparable with eccentric training and superior to wait-
and-see. Those investigators also concluded that moderate
evidence exists for ESWT being equal to sham ESWT for
individuals with patellar tendinopathy. A systematic
review published in 2016 described the results of eccentric
training for tendinopathy of the rotator cuff and lateral
elbow tendinopathy.32 It concluded that eccentric training
may be more effective in treating an upper extremity con-
dition than any other nonoperative form of therapy. How-
ever, this systematic review also lacked strong evidence.
All of the aforementioned systematic reviews suggested
that the evidence for tendon disorder treatment is at best
moderate to low. Yet, we do not recommend stem cell ther-
apy as an alternative to these therapies. This is because of
the invasive character of stem cells and their potential side
effects. In the sections below, we explain the working mech-
anism and potential adverse effects of stem cells that merit
further consideration before the limited evidence is put into
practice.
Theoretical Evidence for the Efficacy
of Stem Cell Therapy
Stem cells may be derived from many different tissues. In
the studies included in this review, cells were derived from
either bone marrow (BMACs, BMMCs, MSCs) or adipose
tissue (allo-ASC). In most studies, plain unsorted cells were
administered with an unknown number of stem cells. Only
1 study described a correlation between the actual number
of stem cells (CD34þ) and treatment outcome.14
There are 2 theories on the efficacy of stem cell treat-
ments for tendon disorders. It is thought that tendon heal-
ing is supported by paracrine effects of injected stem cells,
secreting various growth factors and cytokines that may
mend injured tendons.2,6,8,24,26,27 Theoretically, tendon
healing may also be improved by stem cell differentiation
into tenocytes. In vitro studies have shown stem cell ther-
apies to provide tendon regeneration rather than repair of
the tendon tissue.49 This regeneration includes replace-
ment of the damaged tendon fibers with identical “new”
tissue.49 Regeneration occurs in all embryos, hardly ever
occurs in neonates, and is never observed in adults.46 In
contrast to regeneration, tendon repair is a more rapid pro-
cess encompassing the inflammatory cell cascade, the depo-
sition of matrix, and remodeling.30 Tendon tissue
regeneration is an alternative for replacement of large
damaged tissue based on a combination of embryonic or
adult stem cells.36
Stem Cells and Their Potential to Harm
Stem cells may cause serious harm despite their potential
to heal. Recently, the Food and Drug Administration
warned of serious potential risks to patients from stem cell
therapies administered for uses other than hematopoietic
or immunologic reconstitution.35 Numerous infections were
reported after receipt of bacterially contaminated umbilical
cord blood–derived stem cell products. Autologous hemato-
poietic stem cells injected into the kidneys of a patient with
renal failure were associated with the development of
tumors that eventually led to nephrectomy.45 In another
instance, autologous stem cells derived from adipose tissue
and injected intravitreally into the eyes of people with mac-
ular degeneration were associated with worsening vision in
3 people, 2 of whom became blind.21 A patient who under-
went intrathecal mesenchymal, embryonic, and fetal neu-
ral stem cell infusions for the treatment of an ischemic
stroke developed a glioma that was derived from the
injected stem cells.7 In cases of stem cell administration for
tendon healing, adverse effects have not been reported. As
shown in bone marrow–derived stem cells and ASCs, there
is risk of ectopic bone and tumor formation under special
circumstances.25
Given the paucity of studies following patients with ten-
don disorders after a stem cell injection for prolonged
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periods of time, the extent to which stem cell therapy is
associated with serious harm is presently unknown.
Future Directions
Due to considerable bias and lack of high-level evidence
supporting the use of stem cell therapy, we are currently
not able to recommend stem cell therapy for patients with
tendon disorders. Many gaps in our knowledge remain with
regard to safety, indications, dosage, and concentration of
the stem cells and harvesting methods.10,13,14,17 There is a
need for large, methodologically sound RCTs that are
reported according to the CONSORT (Consolidated Stan-
dards of Reporting Trials) statement.38 Considering the
available evidence, RCTs should compare stem cell therapy
to evidence-based treatments like ESWT and exercise ther-
apy.11,29 Another issue that warrants attention is the stan-
dardized evaluation and reporting of potential harmful
effects of stem cell therapies. Follow-up should be at least
5 years to monitor possible severe harmful effects.
Strengths and Limitations
We used a sensitive search strategy in 6 different databases
and assessed risk of bias based on the latest standards. We
also included 1 trial investigating the combination of stem
cell therapy with PRP injection.17 We believe this combina-
tion of PRP with stem cells is relevant in the evaluation of
the efficacy of stem cell therapy for tendon disorders and,
therefore, is a strength of this review. A limitation is the
absence of information about ongoing studies, despite our
best efforts to obtain such information.
CONCLUSION
Despite promising results of various individual studies on
the use of stem cells in the treatment of various tendon
disorders, there is currently no high-level evidence that
justifies an evidence-based recommendation of stem cell
therapy. Stem cell injections should not be used in clinical
practice given the lack of knowledge about potentially seri-
ous adverse effects.
ACKNOWLEDGMENT
The authors thank Rik J. Molenaars, MD, Harvard
Medical School, Sports Medicine Center (Massachusetts
General Hospital), Boston, Massachusetts, USA, for
proofreading this manuscript and optimizing the use of
language.
SUPPLEMENTAL MATERIAL




1. Ackermann PW, Renstrom P. Tendinopathy in sport. Sports Health.
2012;4(3):193-201.
2. Ahmad Z, Henson F, Wardale J, Noorani A, Tytherleigh-Strong G,
Rushton N. Regenerative techniques for repair of rotator cuff tears.
J Orthop Surg. 2013;21(2):226-231.
3. Albano JJ, Alexander RW. Autologous fat grafting as a mesenchymal
stem cell source and living bioscaffold in a patellar tendon tear. Clin J
Sport Med. 2011;21(4):359-361.
4. Albers IS, Zwerver J, Diercks RL, Dekker JH, Van den Akker-Scheek I.
Incidence and prevalence of lower extremity tendinopathy in a Dutch
general practice population: a cross sectional study. BMC. 2016;17:
16.
5. Andres BM, Murrell GA. Treatment of tendinopathy: what works, what
does not, and what is on the horizon. Clin Orthop Relat Res. 2008;
466(7):1539-1554.
6. Bedi A, Maak T, Walsh C, et al. Cytokines in rotator cuff degeneration
and repair. J Shoulder Elbow Surg. 2012;21(2):218-227.
7. Berkowitz AL, Miller MB, Mir SA, et al. Glioproliferative lesion of the
spinal cord as a complication of “stem-cell tourism.” N Engl J Med.
2016;375(2):196-198.
8. Branford OA, Klass BR, Grobbelaar AO, Rolfe KJ. The growth factors
involved in flexor tendon repair and adhesion formation. J Hand Surg
Eur Vol. 2014;39(1):60-70.
9. Braune C, von Eisenhart-Rothe R, Welsch F, Teufel M, Jaeger A. Mid-
term results and quantitative comparison of postoperative shoulder
function in traumatic and non-traumatic rotator cuff tears. Arch
Orthop Trauma Surg. 2003;123(8):419-424.
10. Chen JL, Zhang W, Liu ZY, et al. Physical regulation of stem cells
differentiation into teno-lineage: current strategies and future direc-
tion. Cell Tissue Res. 2015;360(2):195-207.
11. Dimitrios S, Pantelis M, Kalliopi S. Comparing the effects of eccentric
training with eccentric training and static stretching exercises in the
treatment of patellar tendinopathy: a controlled clinical trial. Clin
Rehabil. 2012;26(5):423-430.
12. Ellera Gomes JL, da Silva RC, Silla LM, et al. Conventional rotator cuff
repair complemented by the aid of mononuclear autologous stem
cells. Knee Surg Sports Traumatol Arthrosc. 2012;20(2):373-377.
13. Gaspar D, Spanoudes K, Holladay C, et al. Progress in cell-based
therapies for tendon repair. Adv Drug Deliv Rev. 2015;84:240-256.
14. Hernigou P, Flouzat Lachaniette CH, Delambre J, et al. Biologic aug-
mentation of rotator cuff repair with mesenchymal stem cells during
arthroscopy improves healing and prevents further tears: a case-
controlled study. Int Orthop. 2014;38(9):1811-1818.
15. Hospital San Carlos, Madrid. Mesenchymal stem cell (MSC) included
in OrthADAPT membrane for rotator cuff tears repair (msctendonrep).
ClinicalTrials.gov identifier: NCT01687777. https://clinicaltrials.gov/
ct2/show/NCT01687777. Published September 19, 2012. Accessed
December 15, 2019.
16. Jiang D, Gao P, Zhang Y, et al. Combined effects of engineered
tendon matrix and GDF-6 on bone marrow mesenchymal stem
cell-based tendon regeneration. Biotechnol Lett. 2016;38(5):
885-892.
17. Kim SJ, Kim EK, Kim SJ, et al. Effects of bone marrow aspirate con-
centrate and platelet-rich plasma on patients with partial tear of the
rotator cuff tendon. J Orthop Surg Res. 2018;13(1):1.
18. Kim YS, Sung CH, Chung SH, et al. Does an injection of adipose-
derived mesenchymal stem cells loaded in fibrin glue influence rotator
cuff repair outcomes? A clinical and magnetic resonance imaging
study. Am J Sports Med. 2017;45(9):2010-2018.
19. Korakakis V, Whiteley R, Tzavara A, et al. The effectiveness of extra-
corporeal shockwave therapy in common lower limb conditions: a
systematic review including quantification of patient-rated pain
reduction. Br J Sports Med. 2018;52(6):387-407.
20. Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal
injection of autologous “stem cells” for AMD. N Engl J Med. 2017;
376(11):1047-1053.
The Orthopaedic Journal of Sports Medicine Efficacy of Stem Cell Therapy for Tendon Disorders 9
21. Lazarides AL, Alentorn-Geli E, Choi JH, et al. Rotator cuff tears in
young patients: a different disease than rotator cuff tears in elderly
patients. J Shoulder Elbow Surg. 2015;24(11):1834-1843.
22. Lee SY, Kim W, Lim C, et al. Treatment of lateral epicondylosis by
using allogeneic adipose-derived mesenchymal stem cells: a pilot
study. Stem Cells. 2015;33(10):2995-3005.
23. Lian OB, Engebretsen L, Bahr R. Prevalence of jumper’s knee among
elite athletes from different sports: a cross-sectional study. Am J
Sports Med. 2005;33(4):561-567.
24. Liu H, Zhu S, Zhang C, et al. Crucial transcription factors in tendon
development and differentiation: their potential for tendon regenera-
tion. Cell Tissue Res. 2014;356(2):287-298.
25. Liu L, Hindieh J, Leong DJ, et al. Advances of stem cell based-
therapeutic approaches for tendon repair. J Orthop Translat. 2017;
9:69-75.
26. Maffulli N, Wong J, Almekinders LC. Types and epidemiology of ten-
dinopathy. Clin Sports Med. 2003;22(4):675-692.
27. Meirelles Lda S, Fontes AM, Covas DT, et al. Mechanisms involved in
the therapeutic properties of mesenchymal stem cells. Cytokine
Growth Factor Rev. 2009;20(5-6):419-427.
28. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items
for Systematic Reviews and Meta-Analyses: the PRISMA statement.
BMJ. 2009;339:B2535.
29. Murphy MC, Travers MJ, Chivers P, et al. Efficacy of heavy eccentric
calf training for treating mid-portion Achilles tendinopathy: a system-
atic review and meta-analysis. Br J Sports Med. 2019;53:1070-1077.
30. Oakes BW. Orthopaedic tissue engineering: from laboratory to the
clinic. Med J Aust. 2004;180(5)(suppl):S35-S38.
31. Ohberg L, Alfredson H. Ultrasound guided sclerosis of neovessels in
painful chronic Achilles tendinosis: pilot study of a new treatment. Br J
Sports Med. 2002;36(3):173-175.
32. Ortega-Castillo M, Medina-Porqueres I. Effectiveness of the eccentric
exercise therapy in physically active adults with symptomatic shoul-
der impingement or lateral epicondylar tendinopathy: a systematic
review. J Sci Med Sport. 2016;19(6):438-453.
33. Pas H, Moen MH, Haisma HJ, et al. No evidence for the use of stem
cell therapy for tendon disorders: a systematic review. Br J Sports
Med. 2017;51(13):996-1002.
34. Pascual-Garrido C, Rolon A, Makino A. Treatment of chronic patellar
tendinopathy with autologous bone marrow stem cells: a 5-year-
followup. Stem Cells Int. 2012;2012:953510.
35. Perkins KM, Spoto S, Rankin DA, et al. Notes from the field: infections
after receipt of bacterially contaminated umbilical cord blood-derived
stem cell products for other than hematopoietic or immunologic
reconstitution—United States, 2018. MMWR Morb Mortal Wkly Rep.
2018;67(50):1397-1399.
36. Protzman NM, Stopyra GA, Hoffman JK. Biologically enhanced heal-
ing of the human rotator cuff: 8-month postoperative histological eval-
uation. Orthopedics. 2013;36(1):38-41.
37. Ruzzini L, Longo UG, Rizzello G, et al. Stem cells and tendinopathy:
state of the art from the basic science to clinic application. Muscles
Ligaments Tendons J. 2012;2(3):235-238.
38. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement:
updated guidelines for reporting parallel group randomised trials.
BMJ. 2010;340:C332.
39. Seoul National University Hospital. Treatment of tendon injury using
allogenic adipose-derived mesenchymal stem cells (rotator cuff tear).
ClinicalTrials.gov identifier: NCT02298023. https://clinicaltrials.gov/
ct2/show/NCT02298023. Posted November 21, 2014. Accessed
December 15, 2019.
40. Seoul National University Hospital. Treatment of tendon injury using
mesenchymal stem cells (ALLO-ASC). ClinicalTrials.gov identifier:
NCT01856140. https://clinicaltrials.gov/ct2/show/NCT01856140.
Posted May 17, 2013. Accessed December 15, 2019.
41. Stein BE, Stroh DA, Schon LC. Outcomes of acute Achilles tendon
rupture repair with bone marrow aspirate concentrate augmentation.
Int Orthop. 2015;39(5):901-905.
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